PBLA / Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication

MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeuti more_horizontal

MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disru more_horizontal

Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants James Carbonara - Investor more_horizontal

Panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data from a late-stage study of ivospemin in the trea more_horizontal

Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants James Carbonara - Hayden IR Jen more_horizontal

MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutic more_horizontal

Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent- more_horizontal

Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants James Carbonara - Hayden IR more_horizontal